Evidence map›Paper›PMID 25741008›Full record

ArticleJournal of virology2015

Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry.

Aileen O'Hearn, Minxiu Wang, Han Cheng, Calli M Lear-Rooney, Katie Koning, Emily Rumschlag-Booms, Elizabeth Varhegyi, Gene Olinger, Lijun Rong

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Host Glycan-Lectin Interplay in SARS-CoV-2 Infection.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Pathogens that infect mammalian cells via sulfonated glycosaminoglycans.Frontiers in cellular and infection microbiology · 2025
    Review
  9. Molecular determinants of cross-species transmission in emerging viral infections.Microbiology and molecular biology reviews : MMBR · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Ebola Virus Entry Inhibitors.Advances in experimental medicine and biology · 2022
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Aileen O'HearnDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Minxiu WangDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Han ChengDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Calli M Lear-RooneyU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Katie KoningDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Emily Rumschlag-BoomsDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Elizabeth VarhegyiDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Gene OlingerU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Lijun RongDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA lijun@uic.edu.
University of Illinois Chicago · USUnited States Army Medical Research Institute of Infectious Diseases · US

Funding

Screening and development of anti-Ebola entry inhibitorsU01AI077767 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RONG, LIJUN · 2009 to 2010
$2.1M
Elucidatng the Entry Mechanism of Ebola VirusesR01AI059570 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RONG, LIJUN · 2005 to 2009
$1.6M
NIAID NIH HHS AI059570NIAID NIH HHS AI77767NIAID NIH HHS R01 AI059570NIAID NIH HHS U01 AI077767
6 · The paper itself

Abstract

unlabelledFiloviruses, including both Ebola virus (EBOV) and Marburg virus (MARV), can infect humans and other animals, causing hemorrhagic fever with a high mortality rate. Entry of these viruses into the host is mediated by a single filoviral glycoprotein (GP). GP is composed of two subunits: GP1, which is responsible for attachment and binding to receptor(s) on susceptible cells, and GP2, which mediates viral and cell membrane fusion. Although numerous host factors have been implicated in the entry process, the initial attachment receptor(s) has not been well defined. In this report, we demonstrate that exostosin 1 (EXT1), which is involved in biosynthesis of heparan sulfate (HS), plays a role in filovirus entry. Expression knockdown of EXT1 by small interfering RNAs (siRNAs) impairs GP-mediated pseudoviral entry and that of infectious EBOV and MARV in tissue cultured cells. Furthermore, HS, heparin, and other related glycosaminoglycans (GAGs), to different extents, can bind to and block GP-mediated viral entry and that of infectious filoviruses. These results strongly suggest that HS and other related GAGs are attachment receptors that are utilized by filoviruses for entry and infection. These GAGs may have therapeutic potential in treating EBOV- and MARV-infected patients. IMPORTANCE: Infection by Ebola virus and Marburg virus can cause severe illness in humans, with a high mortality rate, and currently there is no FDA-approved vaccine or therapeutic treatment available. The ongoing 2014 outbreak in West Africa underscores a lack of our understanding in the infection and pathogenesis of these viruses and the urgency of drug discovery and development. In this study, we provide several pieces of evidence that demonstrate that heparan sulfate and other closely related glycosaminoglycans are the molecules that are used by filoviruses for initial attachment. Furthermore, we demonstrate that these glycosaminoglycans can block entry of and infection by filoviruses. Thus, this work provides mechanistic insights on the early step of filoviral infection and suggests a possible therapeutic option for diseases caused by filovirus infection.

Indexed as

Virus InternalizationAnimalsCell LineEbolavirusExostosin 1FiloviridaeFiloviridae InfectionsGene Knockdown TechniquesGlycosaminoglycansHEK293 CellsHeparan SulfateHeparinHost-Pathogen InteractionsHumansMarburgvirusMiceExostosin 1GlycosaminoglycansHeparan SulfateHeparinN-AcetylglucosaminyltransferasesReceptors, VirusViral Proteins

Identifiers

PMID25741008
PMCPMC4442511
OpenAlexW2105513391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.